Workflow
3 Things You Need to Know If You Buy Pfizer Today
PFEPfizer(PFE) The Motley Fool·2025-02-18 09:35

Core Insights - Pfizer's revenue peaked at over 100billionin2022duetoitscoronavirusproducts,buthassincedeclinedasdemandfortheseproductshasdecreased[1][2]Group1:RevenueandGrowthPotential−Thegrowthfromcoronavirusproductsshouldnotbethebenchmarkforfuturerevenue;instead,pre−pandemicsalesshouldbeconsidered[3][4]−Full−year2019revenuewasapproximately100 billion in 2022 due to its coronavirus products, but has since declined as demand for these products has decreased [1][2] Group 1: Revenue and Growth Potential - The growth from coronavirus products should not be the benchmark for future revenue; instead, pre-pandemic sales should be considered [3][4] - Full-year 2019 revenue was approximately 51 billion, with potential non-COVID revenue projected to exceed 80billionby2030,indicatinga5580 billion by 2030, indicating a 55% increase [5] Group 2: Product Exclusivity and Strategy - Pfizer is facing a loss of exclusivity on major products, which could result in 17 billion in lost sales from 2025 to 2030 [6][7] - The company is preparing for this by launching new products and enhancing its oncology business through the acquisition of Seagen, with 19 product releases planned over 18 months [8][10] Group 3: Transformation Timeline - The transformation to boost growth will take time, with Pfizer aiming for $4.5 billion in cost savings by the end of the year [11] - The stock may take time to appreciate, but it is currently trading at 8x forward earnings estimates, presenting a potential buying opportunity for investors [12]